Focus: MyOme is a genomic analysis company focused on risk stratification and disease diagnosis across neurology, cardiovascular, and rare diseases. The company operates as a pre-revenue or early-stage biotech with a small, growing team based in Palo Alto.
Profile data last refreshed 4h ago · AI intelligence enriched 3w ago
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
MyOme represents a high-risk, high-upside genomics play best suited to early-career scientists or technologists comfortable with pre-revenue risk and strong conviction in the genomic-stratification thesis.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MyOme
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MyOme's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
MyOme Strengthens Board with Appointment of Two Healthcare Leaders - PR Newswire
MyOme Strengthens Board with Appointment of Two Healthcare Leaders PR Newswire
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis - BioSpace
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis BioSpace
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo